Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,924 recruiting studies in this area right now.
By phase
- Not applicable2,025
- Phase 21,074
- Phase 1791
- Phase 1/Phase 2480
- Phase 3345
- Phase 4125
- Phase 2/Phase 384
Top conditions
- Multiple Myeloma328
- Acute Myeloid Leukemia279
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia96
- Follicular Lymphoma70
- Hematologic Malignancy67
- Hodgkin Lymphoma64
- Myelodysplastic Syndrome64
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm54
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center57
- Mayo Clinic56
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital45
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama157
- Maryland152
- Arizona126
- Florida104
- Massachusetts104
- New York98
- Ohio71
- Minnesota69
Recruiting studies4,924 total
- NCT06669247RecruitingPhase 1/Phase 2
Study of REGN7945 plus linvoseltamab for relapsed or refractory multiple myeloma
This study tests a new combination of two drugs (REGN7945 and linvoseltamab) for people with multiple myeloma that has come back or not responded to at least 3 prior treatments. The goal is to see if the combination is safe and effective, and it may offer a new option if other therapies have stopped working.
Sydney, New South WalesAges 18 years+ - NCT06664411RecruitingPhase 2
Pola-ZR2P for untreated DLBCL
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
Beijing, Beijing MunicipalityAges 14 years+ - NCT06665997RecruitingPhase 4
Depot shot for pain in women with sickle cell disease
This study tests if a hormone shot (depot medroxyprogesterone acetate) can help reduce pain episodes in women with sickle cell disease. It aims to see if the shot improves pain and markers of inflammation.
Atlanta, GeorgiaAges 18–50 - NCT06665490Enrolling by invitation
Skin care wash study for mycosis fungoides
This study tests whether a special skin care body wash can improve skin lesions in people with mycosis fungoides, a type of skin lymphoma. Researchers will look at skin bacteria before and after using the wash.
Chicago, IllinoisAges 18–89 - NCT06664970Enrolling by invitationPhase 2
Treatment for MDS/MPN Overlap Syndrome
This study tests a combination of two drugs (azacitidine or ruxolitinib plus selinexor) for people with MDS/MPN overlap syndrome, a type of blood cancer. It aims to see if this treatment helps control symptoms and improve blood counts.
BeijingAges 18 years+ - NCT06664541Enrolling by invitation
Gene therapy decisions and quality of life
This study looks at how people with blood diseases and their families make decisions about gene therapy, and how it affects their quality of life. It involves interviews or surveys to understand your experience.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06664229Recruiting
Dementia and fall prevention program for older adults
This study tests a pressure sensor-based program to help prevent dementia and falls in older adults. If you are 65 or older, can walk independently, and have no dementia or other conditions that affect thinking, you may be able to join.
Seoul, SeoulAges 65 years+ - NCT06660368RecruitingPhase 2
A study of a drug combo for relapsed or refractory AML
This trial tests a combination of targeted therapy (venetoclax) and chemotherapy (cladribine, cytarabine, G-CSF, mitoxantrone) for people with acute myeloid leukemia that has come back or not responded to previous treatment. It aims to see if this combination can help achieve remission.
Tampa, FloridaAges 18–80 - NCT06666712RecruitingPhase 1
Chronic brain infusion of topotecan for recurrent glioma
This trial tests a treatment called topotecan that is delivered directly into the brain through a small tube (convection-enhanced delivery). It is for people whose IDH-mutant glioma has come back despite standard treatment. The goal is to see if this approach can help control the tumor.
New York, New YorkAges 18 years+ - NCT06668584RecruitingPhase 2
Olutasidenib to prevent cancer return after stem cell transplant
This study tests if a daily pill called olutasidenib can help keep your cancer from coming back after a stem cell transplant. It's for people with a specific IDH1 gene change and myeloid cancers like AML or MDS.
Houston, TexasAges 18–75 - NCT06497738Recruiting
Comparing two drug combos for elderly myeloma
This trial compares two different drug combinations (DRd and VRd-lite) for older adults (65+) who are newly diagnosed with multiple myeloma. The goal is to see which combination works better and is easier to tolerate.
Changzhou, JiangsuAges 65 years+ - NCT06219356RecruitingPhase 1
Study of GLB-002 for relapsed or refractory non-Hodgkin lymphoma
This trial tests a new drug, GLB-002, for people with non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. The goal is to see if GLB-002 is safe and whether it can help shrink or control the lymphoma.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06378437RecruitingPhase 1
GLB-001 for blood cancers that have returned or not responded
This trial is testing a new drug called GLB-001 for people with certain blood cancers or bone marrow disorders that have not gotten better with standard treatments. The goal is to see if the drug is safe and how well it works.
Hefei, AnhuiAges 18 years+ - NCT06616389RecruitingPhase 1/Phase 2
OsteoDex for multiple myeloma in previously treated patients
This study tests a new drug called OsteoDex (ODX) for people with multiple myeloma whose cancer has continued to worsen after trying 1 to 5 earlier treatments. The goal is to see if OsteoDex can help control the disease.
StockholmAges 18 years+ - NCT06650813Recruiting
Adapting a fatigue program for sickle cell disease
This trial adapts the FACETS program, a fatigue-management course, for people with sickle cell disease. It aims to help participants better cope with fatigue and improve daily life.
GrenobleAges 18 years+ - NCT06649812RecruitingPhase 2
Testing a combination targeted therapy (ViPOR) for aggressive B-cell lymphoma
This trial tests a new combination of targeted drugs called ViPOR for people with aggressive B-cell lymphoma that has come back or not responded to previous treatment. The goal is to see if this treatment can help when standard therapies haven't worked.
Tucson, ArizonaAges 18 years+ - NCT06652633RecruitingPhase 3
Long-term follow-up of Galapagos CAR T-cell therapy recipients
This study is for people who have already received a specific type of cell therapy (CAR T-cell therapy) made by Galapagos. It will follow them over the long term to see how they are doing.
Boston, MassachusettsAges 18 years+ - NCT06651970RecruitingPhase 4
Acalabrutinib for chronic lymphocytic leukemia with heart problems
This trial tests a targeted therapy called acalabrutinib (a pill) against other standard treatments for chronic lymphocytic leukemia (CLL) in people who also have heart conditions. The goal is to see if acalabrutinib is a safer or more effective option for this group.
Charlotte, North CarolinaAges 18–130 - NCT06647017Recruiting
Nerve stimulation to reduce blood loss during dialysis graft placement
This trial tests whether a gentle nerve stimulation device placed behind the ear can lower blood loss during surgery to place a dialysis graft (a tube for dialysis treatment). It may help make the procedure safer.
Watkinsville, GeorgiaAges 18–75 - NCT06656494RecruitingPhase 1
New drug combo for myeloid blood cancers
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
Orange, CaliforniaAges 18 years+ - NCT06646497RecruitingPhase 2
Stem cell transplant for tough aplastic anemia in adults 40-60
This study is testing whether a stem cell transplant (from a matched relative, unrelated donor, or half-matched donor) can help adults aged 40–60 with severe aplastic anemia that didn't get better or came back after standard treatments.
Paris, FranceAges 40–60 - NCT06646978Enrolling by invitation
Long-term cancer risk in CML treatment trial
This study follows people who took part in the French SPIRIT trial for chronic myeloid leukemia (CML) to see if they develop other cancers later in life. It helps doctors understand the long-term safety of imatinib-based treatments.
PoitiersAges 18 years+ - NCT06649227RecruitingPhase 1
CD19 CAR-T cells for hard-to-treat AML
This study tests a new type of immunotherapy (CAR-T cells that target CD19) for adults with acute myeloid leukemia (AML) that has not responded to treatment or has come back. It aims to see if these CAR-T cells are safe and can help control the leukemia.
LilleAges 18 years+ - NCT06647979RecruitingPhase 1
Gene editing for severe sickle cell or thalassemia
This trial tests a new gene therapy that edits your own blood stem cells to help them make more fetal hemoglobin, which can prevent sickling and reduce the need for transfusions. It is for people with severe sickle cell disease or beta thalassemia who do not have a matched sibling donor.
Boston, MassachusettsAges 13–40
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,924 recruiting hematology studies from the U.S. registry right now, out of 7,354 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.